Topic is suspended
 
Status Suspended
Process TAG

Timeline

Key events during the development of the guidance:

Date Update
09 March 2020 Suspended, Topic is suspended
09 March 2020 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of masitinib for treating malignant melanoma that has a c-Kit juxtamembrane mutation. Following on from information received from the company NICE has decided to suspend this appraisal from its current work programme as company are no longer intending to submit a Marketing Authorisation Application to the European Medicines Agency for this indication at this time. NICE will continue to monitor development and will update interested parties as and when the situation changes.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance